Table 2.
HIV‐related characteristics of people living with HIV (PLWH)
| Number of patients | 1041 |
| HIV transmission mode [n (%)] | |
| Heterosexual contact | 310 (29.8) |
| Male‐to‐male sexual contact | 548 (52.6) |
| Intravenous drug use | 140 (13.4) |
| Other/unknown | 43 (4.1) |
| Time since HIV diagnosis (years) [median (IQR)] | 11.6 (6.9–17.5) |
| Duration of ART (years) [median (IQR)] | 9.0 (4.6–13.5) |
| Subjects receiving ART [n (%)] | 1009 (96.9) |
| Characteristics of the present ART [n (%)] | |
| Subjects taking TDF | 167 (16.0) |
| Subjects taking TAF | 534 (51.3) |
| Subject taking ABC | 270 (25.9) |
| Subjects taking NNRTI | 285 (27.4) |
| Subjects taking PI | 203 (19.5) |
| Subjects taking INSTI | 612 (58.8) |
| Most recent CD4 count (cells/μL) [median (IQR)] | 656 (496–851) |
| CD4 count < 200 [n (%)] | 7 (0.7) |
| CD4 count ≥ 200 to < 350 [n (%)] | 63 (6.1) |
| CD4 count ≥ 350 to < 500 [n (%)] | 184 (17.7) |
| CD4 count ≥ 500 [n (%)] | 751 (72.1) |
| Most recent HIV‐1 RNA [n (%)] | |
| Subjects with < 50 copies/mL | 971 (93.4) |
| Subjects with 50–400 copies/mL | 24 (2.3) |
| Subjects with > 400 copies/mL | 4 (0.4) |
| CD4 nadir count (cells/μL) [median (IQR)] | 266 (160–356) |
| CD4 nadir count < 200 [n (%)] | 335 (32.2) |
| CD4 nadir count ≥ 200 to < 350 [n (%)] | 403 (38.7) |
| CD4 nadir count ≥ 350 to < 500 [n (%)] | 170 (16.3) |
| CD4 nadir count ≥ 500 [n (%)] | 91 (8.7) |
IQR, interquartile range; ART, antiretroviral therapy; TDF, tenofovir disoproxil fumarate; TAF, tenofovir alafenamide; ABC, abacavir; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor; INSTI, integrase strand transfer inhibitor.